{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:44:04Z","timestamp":1784191444045,"version":"3.55.0"},"reference-count":26,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"abstract":"<jats:p>In some parts of the world, measles vaccination has resulted in very substantial reductions in measles-related morbidity and mortality. Even so, it has been estimated that 30 million people still contract the disease every year, that nearly 1 million of these die, and that measles-related deaths account for about 10% of all deaths in children under the age of 5 in developing countries. Existing evidence from controlled trials suggests that antibiotic prophylaxis in measles can result in important reductions in measles-related morbidity, and, at a World Health Organization meeting convened in 1993 to decide on research priorities for the treatment of measles, highest priority was accorded to additional controlled trials of prophylactic antibiotics. As controlled trials of vitamin A in measles have made clear, such trials are feasible. Continued acquiescence in uncertainties about the effects of prophylactic antibiotics in a disease that continues to afflict so many children worldwide is unacceptable.<\/jats:p>","DOI":"10.1542\/peds.109.2.312","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"312-315","source":"Crossref","is-referenced-by-count":11,"title":["Why We Need to Know Whether Prophylactic Antibiotics Can Reduce Measles-Related Morbidity"],"prefix":"10.1542","volume":"109","author":[{"given":"Iain","family":"Chalmers","sequence":"first","affiliation":[{"name":"UK Cochrane Centre&#x2028; NHS Research and Development Programme&#x2028; Summertown Pavilion&#x2028; Middle Way&#x2028; Oxford OX2 7LG, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2002,2,1]]},"reference":[{"key":"2021121006164467000_R1","doi-asserted-by":"crossref","unstructured":"McCarthy M. Measles eradication may be near in the Americas. Lancet.2000;356:1247","DOI":"10.1016\/S0140-6736(05)73850-2"},{"key":"2021121006164467000_R2","doi-asserted-by":"crossref","unstructured":"Measles, MMR, and autism: the confusion continues [editorial]. Lancet.2000;355:1379","DOI":"10.1016\/S0140-6736(00)02129-2"},{"key":"2021121006164467000_R3","doi-asserted-by":"crossref","unstructured":"Ahmad K. \u201cAlarming\u201d measles epidemic kills hundreds in Afghanistan. Lancet.2000;335:998","DOI":"10.1016\/S0140-6736(05)74746-2"},{"key":"2021121006164467000_R4","unstructured":"World Health Organization. Clinical Research on Treatment of Measles: Report of a Meeting. Geneva, Switzerland: World Health Organization;1995. WHO\/CDR\/95.15"},{"key":"2021121006164467000_R5","doi-asserted-by":"crossref","unstructured":"Sheldon T. Netherlands faces measles epidemic. BMJ.2000;320:76","DOI":"10.1136\/bmj.320.7227.76"},{"key":"2021121006164467000_R6","unstructured":"Skrabanek P, McCormick J. Follies and Fallacies in Medicine. Glasgow, United Kingdom: Taragon;1989"},{"key":"2021121006164467000_R7","doi-asserted-by":"crossref","unstructured":"Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA.1992;268:240\u2013248","DOI":"10.1001\/jama.268.2.240"},{"key":"2021121006164467000_R8","unstructured":"Lightfoot L, Rogers L. Hundreds killed by doctors relying on outdated manuals. The Sunday Times. February 5,1995:1\u20132"},{"key":"2021121006164467000_R9","doi-asserted-by":"crossref","unstructured":"Samb B, Simondon F, Aaby P, Whittle H, Seck AM. Prophylactic use of antibiotics and reduced case fatality in measles infection. Pediatr Infect Dis J.1995;14:695\u2013696","DOI":"10.1097\/00006454-199508000-00009"},{"key":"2021121006164467000_R10","doi-asserted-by":"crossref","unstructured":"Shann F. Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence. BMJ.1997;314:334\u2013336","DOI":"10.1136\/bmj.314.7077.334"},{"key":"2021121006164467000_R11","doi-asserted-by":"crossref","unstructured":"Hussey G. Managing measles. BMJ.1997;314:316\u2013317","DOI":"10.1136\/bmj.314.7077.316"},{"key":"2021121006164467000_R12","doi-asserted-by":"crossref","unstructured":"Berlin JA. Summary statistics of poor quality studies must be treated cautiously. BMJ.1997;314:337","DOI":"10.1136\/bmj.314.7077.337"},{"key":"2021121006164467000_R13","doi-asserted-by":"crossref","unstructured":"Anderson T. Sulphanilamide in the treatment of measles. BMJ.1939;i:716\u2013718","DOI":"10.1136\/bmj.1.4083.716"},{"key":"2021121006164467000_R14","doi-asserted-by":"crossref","unstructured":"Karelitz S, King H, Curtis B, Wechsel M. Use of aureomycin and penicillin in the treatment of rubeola in the pre-eruptive and early eruptive phase. Pediatrics.1951;7:193\u2013199","DOI":"10.1542\/peds.7.2.193"},{"key":"2021121006164467000_R15","unstructured":"Prasad R, Mathur GP, Trehan OP, Mehrotra ML, Dayal RS. A clinical and radiological study of measles. Indian Pediatr.1967;4:243\u2013250"},{"key":"2021121006164467000_R16","doi-asserted-by":"crossref","unstructured":"Shann F, D\u2019Souza RM, D\u2019Souza R. Antibiotics for preventing pneumonia in children with measles [Cochrane Review]. In: The Cochrane Library, Issue 2. Oxford, United Kingdom: Update Software;1999","DOI":"10.1002\/14651858.CD001477"},{"key":"2021121006164467000_R17","doi-asserted-by":"crossref","unstructured":"Shann F, D\u2019Souza RM, D\u2019Souza R. Antibiotics for preventing pneumonia in children with measles [Cochrane Review]. In: The Cochrane Library, Issue 1. Oxford, United Kingdom: Update Software;2000","DOI":"10.1002\/14651858.CD001477"},{"key":"2021121006164467000_R18","doi-asserted-by":"crossref","unstructured":"Shann F, D\u2019Souza RM, D\u2019Souza R. Antibiotics for preventing pneumonia in children with measles [Cochrane Review]. In: The Cochrane Library, Issue 2. Oxford, United Kingdom: Update Software;2000","DOI":"10.1002\/14651858.CD001477"},{"key":"2021121006164467000_R19","doi-asserted-by":"crossref","unstructured":"Jefferson TG. What are the benefits of editorials and non-systematic reviews?BMJ.1999;318:135","DOI":"10.1136\/bmj.318.7176.135"},{"key":"2021121006164467000_R20","unstructured":"Aaby P, Garly ML, Martins C, Bale\u0301 C, Whittle H. Prophylactic use of antibiotics in measles infection in Guinea-Bissau: a randomized, double blind, placebo controlled trial. Unpublished protocol"},{"key":"2021121006164467000_R21","unstructured":"Priest P. Antibacterial Use and Antibacterial Resistance in the Community [DPhil thesis]. Oxford, United Kingdom: University of Oxford;2001"},{"key":"2021121006164467000_R22","doi-asserted-by":"crossref","unstructured":"Priest P, Yudkin P, McNulty C, Mant D. Antibacterial prescribing and antibacterial resistance in English general practice: a cross sectional study. BMJ.2001;323:1037\u20131041","DOI":"10.1136\/bmj.323.7320.1037"},{"key":"2021121006164467000_R23","doi-asserted-by":"crossref","unstructured":"Bauchner H, Wise PH. Antibiotics without prescription: \u201cbacterial or medical resistance\u201d?Lancet.2000;355:1480","DOI":"10.1016\/S0140-6736(00)02160-7"},{"key":"2021121006164467000_R24","doi-asserted-by":"crossref","unstructured":"D\u2019Souza RM, D\u2019Souza R. Vitamin A for treating measles in children. In: Cochrane Library, Issue 3. Oxford, United Kingdom: Update Software;2001","DOI":"10.1002\/14651858.CD001479"},{"key":"2021121006164467000_R25","doi-asserted-by":"crossref","unstructured":"Aaby P, Bukh J, Lisse IM, Smits AJ. Overcrowding and intensive exposure as determinants of measles mortality. Am J Epidemiol.1984;120:49\u201363","DOI":"10.1093\/oxfordjournals.aje.a113874"},{"key":"2021121006164467000_R26","doi-asserted-by":"crossref","unstructured":"Shann F. Uses of error: the wrong research costs lives. Lancet.2001;357:1691","DOI":"10.1016\/S0140-6736(00)04879-0"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/2\/312\/1113604\/pe0202000312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/2\/312\/1113604\/pe0202000312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:40:27Z","timestamp":1682746827000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/109\/2\/312\/63999\/Why-We-Need-to-Know-Whether-Prophylactic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2002,2,1]]},"published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.109.2.312","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,1]]}}}